Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;47(11):1720-1731.
doi: 10.1111/aor.14616. Epub 2023 Aug 1.

Clinical relevance of cell-free DNA during venovenous extracorporeal membrane oxygenation

Maximilian P Lingel  1 , Moritz Haus  1 , Lukas Paschke  1 , Maik Foltan  1 , Matthias Lubnow  2 , Michael Gruber  3 , Lars Krenkel  4 , Karla Lehle  1
Affiliations

Clinical relevance of cell-free DNA during venovenous extracorporeal membrane oxygenation

Maximilian P Lingel et al. Artif Organs. 2023 Nov.

Abstract

Background: Thrombosis remains a critical complication during venovenous extracorporeal membrane oxygenation (VV ECMO). The involvement of neutrophil extracellular traps (NETs) in thrombogenesis has to be discussed. The aim was to verify NETs in the form of cell-free DNA (cfDNA) in the plasma of patients during ECMO.

Methods: A fluorescent DNA-binding dye (QuantifFluor®, Promega) was used to detect cell-free DNA in plasma samples. cfDNA concentrations from volunteers (n = 21) and patients (n = 9) were compared and correlated with clinical/technical data before/during support, ECMO end and time of a system exchange.

Results: Before ECMO, patients with a median (IQR) age of 59 (51/63) years, SOFA score of 11 (10/15), and ECMO run time of 9.0 (7.0/19.5) days presented significantly higher levels of cfDNA compared to volunteers (6.4 (5.8/7.9) ng/μL vs. 5.9 (5.4/6.3) ng/μL; p = 0.044). Within 2 days after ECMO start, cfDNA, inflammatory, and hemolysis parameters remained unchanged, while platelets decreased (p = 0.005). After ECMO removal at the end of therapy, cfDNA, inflammation, and coagulation data (except antithrombin III) remained unchanged. The renewal of a system resulted in known alterations in fibrinogen, d-dimers, and platelets, while cfDNA remained unchanged.

Conclusion: Detection of cfDNA in plasma of ECMO patients was not an indicator of acute and circuit-induced thrombogenesis.

Keywords: ECMO; blood; cell-free DNA; coagulation; inflammation; neutrophil extracellular traps.

PubMed Disclaimer

References

REFERENCES

    1. Doyle AJ, Hunt BJ. Current understanding of how extracorporeal membrane oxygenators activate haemostasis and other blood components. Front Med (Lausanne). 2018;5:352. https://doi.org/10.3389/fmed.2018.00352
    1. Olson SR, Murphree CR, Zonies D, Meyer AD, Mccarty OJT, Deloughery TG, et al. Thrombosis and bleeding in extracorporeal membrane oxygenation (ECMO) without anticoagulation: a systematic review. ASAIO J. 2021;67:290-296. https://doi.org/10.1097/MAT.0000000000001230
    1. Thomas J, Kostousov V, Teruya J. Bleeding and thrombotic complications in the use of extracorporeal membrane oxygenation. Semin Thromb Hemost. 2018;44:20-29. https://doi.org/10.1055/s-0037-1606179
    1. Lubnow M, Philipp A, Foltan M, Bull Enger T, Lunz D, Bein T, et al. Technical complications during veno-venous extracorporeal membrane oxygenation and their relevance predicting a system-exchange-retrospective analysis of 265 cases. PLoS ONE. 2014;9:e112316. https://doi.org/10.1371/journal.pone.0112316
    1. Murphy DA, Hockings LE, Andrews RK, Aubron C, Gardiner EE, Pellegrino VA, et al. Extracorporeal membrane oxygenation-hemostatic complications. Transfus Med Rev. 2015;29:90-101. https://doi.org/10.1016/j.tmrv.2014.12.001

Substances

LinkOut - more resources